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The constant gardener and industry
sponsored trialsThe film of John Le Carre´’s book, ‘‘The constant
gardener’’ has been nominated for many awards. I
confess that I enjoyed both the book and themovie.
The latter was gorgeously filmed in Kenya and the
acting by Ralph Fiennes and Rachel Weisz was
superb. I hope by the time this is published it would
have won all the prizes. However, the book and the
film are works of fiction. The story is based on an
absurd premise. An evil multinational pharmaceuti-
cal company is trying to get approval for a new anti-
malarial that is active against rapidly developing
resistant strains of the disease. They are testing the
drug in an innocent andna€ıve African population and
literally burying the toxic side effects of their
victims in unmarked mass graves. Along comes
plucky Tessa Quayle played by the lovely Rachel
Weisz who, together with a gay black doctor, un-
covers this plot and is murdered brutally with him.
JustinQuayle played by Fiennes, the kindly ‘‘green’’
diplomat and eponymous gardener, then sets out to
find the truth about his wife’s murder, all is
revealed, the bad guys get their come-uppance
and Justin is in turn murdered against a beautiful
sunset in an ecologically unspoilt landscape (please
noteall thePC subplots).What is so absurd about the
premise behind the plot is that no drug company
could ever hope to get away with it with the current
regulatory systems. Post-marketing surveys of ad-
verse events would rapidly have picked up these
toxic side effects in a Western society and the
company would be taken to the cleaners in class
action litigation. Note the recent furore with the
COX2 inhibitors thatweremarketed in all good faith.
I am reminded of all this by the recent spat
between the BMJ and its American rival JAMA.1,2
Effectively JAMA is advocating an additional layer
of scrutiny for industry sponsored trials, which
whatever gloss is put upon it, suggests that we
can’t trust the drug Barons (Fig. 1).1743-9191/$ - see front matter ª 2006 Surgical Associates Ltd. Pu
doi:10.1016/j.ijsu.2006.01.014I have no doubt where I stand on this having
worked closely with the pharmaceutical industry in
trials developing endocrine therapy for breast
cancer over the last 30 years. To suggest that there
exists systematic corruption at the heart of industry
is not only an insult to industry but also to the
clinical scientists within the company and within
academia who rely on each other’s skills and in-
tegrity to bring safe and effective drugs to the
market. To believe otherwise reflects a belief in the
kind of fantasy world described in ‘‘The constant
gardener’’. Furthermore the editorial policies of
journals such as the International Journal of Surgery
would make it virtually impossible for tarnished
work to slip past our panel of referees.
Do I declare a conflict of interest? You bet I do. I
have an interest in getting effective anticancer
agents to patients as quickly as possible. Along the
way this has helped my career development. I’ve
also received consultancies, honoraria and travel
grants from industry over the years that have gone
a longway inmaking up for the sacrifices in pursuing
an academic career. In fact because almost all
effective drugs and devices are developed by in-
dustry, anyone who can claim that the absence of
these conflicts of interest has probably never
contributed in a major way to progress in medical
science. The exception to this might be the statis-
ticians who carry out the meta-analyses of our work
at the coalface from the sanctity of their ivory
towers. Let’s not be sanctimonious about this but at
the same time we must never drop our guard. The
worst culprits in scientific fraud happen to be
amongst the scientific community themselves as
described by the review paper by Jaffer and
Cameron (available online).3
Finally let’s not forget the ‘‘law of unintended
consequences’’. The continuous sniping at industry
and the dramatic attempts to demonise bigblished by Elsevier Ltd. All rights reserved.
4 EditorialFigure 1 JAMA requires industry funded trials to have an additional layer of institutional oversight (pictures cour-
tesy of iStockphoto.com).pharma, has already lead to a backlash. A recent
report in the journal, Lancet Infectious diseases,
describes increasing difficulty in recruiting volun-
teers in sub-Saharan Africa for trials of anti
retroviral therapy for HIV patients.4
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